To buy or not to buy, that’s the question. For even the most seasoned Wall Street observers, determining the ideal time to pull …
Canaccord analysts debating the impact of recent events on Zynerba and DexCom.
It’s a very rewarding trading day for investors in Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) with shares up over 60%, making the stock Wall Street’s …
Upon releasing negative data for lead drug candidate transdermal CBD (ZYN002) on Monday, Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) investors ran for the hills, sending …
Healthcare analysts expressed their opinions on Myokardia Inc (NASDAQ:MYOK) and Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) after the former released promising clinical data in symptomatic, obstructive hypertrophic …
Investors continue to dump shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) after the drug maker reported initial data from its Phase 2 study with ZYN002 …
Cantor analyst Elemer Piros weighs in with a few insight on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), after the drug maker reported second-quarter results and reiterated its …
H.C.
Many investors hope to win big on biotech stocks as shares can sky rocket when there is good news. Maxim analyst Gabrielle Zhou …
The iShares Nasdaq Biotechnology ETF (IBB) ended 3.8 percent lower Tuesday, as investors reacted harshly toward poor earnings results by pharma giant Valeant Pharmaceuticals …
